[转移贴]Preliminary Success with Hep C Vaccine (Inovio)

ms003

原帖由论坛会员Rojjer发表于 2008-6-4 22:40 ：

Inovio's partner reveals preliminary results indicating reduction in hepatitis C viral load in phase I/II clinical study of ChronVac-C - Quick Facts



Inovio Biomedical Corp. (INO: News, Chart, Quote ) announced that its partner, Tripep AB, reported preliminary results indicating a reduction in hepatitis C viral load in its ongoing phase I/II clinical study of its ChronVac-C therapeutic DNA vaccine. The vaccine is delivered using Inovio's electroporation-based DNA delivery system.

Inovio noted that the result is from the first patient in the middle dose group to complete treatment against hepatitis C virus infection. Samples taken before, during and after treatment show that the viral levels in blood successively reduced by more than 95% during treatment.

In the lowest dose group, two patients who completed treatment developed a T-cell response to hepatitis C. The preliminary result from this first patient to complete treatment in the intermediate dose group is the first to indicate a significant reduction in viral load. The company said that there have been no severe adverse events.